Skip to main content
. 2012 Aug 7;184(11):1247–1254. doi: 10.1503/cmaj.110950

Table 2:

Intention-to-treat analysis of the changes from baseline to 12 weeks in the iron and placebo groups

Variable Mean change (adjusted)* (SD) Treatment effect, mean change (adjusted), (95% CI)
Iron
n = 102
Placebo
n = 96
Fatigue
Fatigue score (CAPPS; 0–40 points)
 Effect on score −12.2 (10.2) −8.7 (11.7) −3.46 (−6.7 to −0.3)
 Change over time, % −47.7 (35.6) −28.8 (57.1) −18.9 (−34.5 to −3.2)
Global fatigue index (MAF; 0–50 points)
 Effect on score −16.2 (11.8) −11.2 (10.8) −4.0 (−7.6 to −0.4)
 Change over time, % −41.3 (30.5) −30.8 (27.6) −10.5 (−19.2 to −1.9)
Severity index of fatigue (MAF; 0–10 points)
 Effect on score −3.6 (2.5) −2.7 (2.3) −0.87 (−1.5 to −0.08)
 Change over time, % −43.3 (30.1) −33.6 (27.5) −9.7 (−18.1 to −1.2)
Blood characteristics
Hemoglobin, g/dL 0.28 (0.79) −0.05 (0.83) 0.32 (0.11 to 0.52)
Ferritin, μg/L 11.6 (13.7) 0.2 (11.0) 11.4 (7.5 to 15.3)
Red blood cells, × 1012/L 0.01 (0.19) −0.02 (0.21) 0.02 (−0.06 to 0.10)
Mean corpuscular volume, fL 1.4 (3.5) −0.6 (3.2) 1.9 (1.1 to 2.7)
Hematocrit, % 0.7 (2.7) −0.4 (2.5) 1.0 (0.2 to 1.7)
Transferrin, g/L −0.17 (0.49) 0.02 (0.38) −0.15 (−0.3 to −0.05)
Soluble transferrin receptor, mg/L −0.66 (0.69) −0.13 (0.51) −0.54 (−0.8 to −0.28)
Transferrin saturation, % 2.8 (14.2) −0.9 (14.1) 3.8 (0.1 to 7.6)
Mental disorders (CAPPS; 0–40 points)
Depression −5.0 (6.5) −4.9 (7.4) 0.04 (−2.0 to 2.1)
Anxiety −5.5 (9.0) −3.5 (9.1) −2.0 (−4.9 to 0.9)
Quality of life
SF–12 (0–100 points) 8.8 (13.4) 6.0 (12.9) 2.8 (−1.2 to 6.8)
 Physical score, SF–12 (0–50 points) 5.4 (8.4) 3.1 (6.8) 2.3 (−0.4 to 5.0)
 Mental score, SF–12 (0–50 points) 3.5 (8.6) 2.7 (8.4) 0.7 (−1.2 to 2.6)
CAPPS total score, (0–120 points) −21.3 (20.5) −16.9 (21.4) −4.4 (−11.2 to 2.4)

Note: CAPPS = Current and Past Psychological Scale, CI = confidence interval, MAF = multidimensional assessment of fatigue scale, SD = standard deviation, SF-12 = short form Self-Reported Health Questionnaire.

*

Mean differences between baseline and 12 weeks were adjusted for clustering effects at the physician level.

Iron = prolonged-release ferrous sulfate (FeSO4).

Generalized estimating equations were used to calculate the average least-squares mean between groups adjusted for baseline values and the clustering effect between physicians. A hot-deck method with 10 imputations was used to account for data that were missing and lost to follow-up.